

San Francisco, CA 94105

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE 10/761,557 01/21/2004 D. James Surmeier NWESTERN-08739 2838 **EXAMINER** 05/17/2006 David A. Casimir CHONG, KIMBERLY MEDLEN & CARROLL, LLP ART UNIT PAPER NUMBER 101 Howard Street, Suite 350

1635 DATE MAILED: 05/17/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) **Advisory Action** 10/761.557 SURMEIER ET AL. Before the Filing of an Appeal Brief Examiner **Art Unit** 1635 Kimberly Chong --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 24 April 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. X The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires ___months from the mailing date of the final rejection. b) X The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: ... (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: 4, 10, 17. Claim(s) rejected: _ Claim(s) withdrawn from consideration: . . . AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

See Continuation Sheet.

11. 🛛 The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s).

13. Other:

Continuation of 11. does NOT place the application in condition for allowance because: Applicant has amended claim 4 to include new sequences that are not in sequence compliance. Claim 4 recites sequences that are not identified by the proper sequence identifier.

Further, the sequences listed in claim 4 referring to target regions of Kv3.4 raise new issues that would require further consideration and/or a new search. The sequences listed appear to recite the siRNA targets as either two separate regions or a region that starts with the first sequence listed in the claim and ends with the second sequence listed in the claim. In either case, this would require a new search for siRNA that targets both regions or the entire region. Applicant disloses the sequences refer to SEQ ID No. 3 (position 1626-1644) and SEQ ID No. 4 (position 1825-1843) and it is unclear whether the siRNA targets the region starting with position 1626 and ending with position 1843 or if the siRNA targets the region 1626-1644 and 1825-1843.

Moreover, in the amendment filed 4/24/06, Applicant describes the above regions as sequence locations for siRNA targets however the specification on page 67 discloses these sequences as specific siRNA (see line 5 "The duplexes used had the following sequences..."). Because the claims are interpreted in view of the specification, claim 17 was interpreted to mean siRNA duplexes selected from the following sequences: SEQ ID NO. 3 or 4.

Furthermore, the amendment will not be entered because although Applicant has complied with the sequence requirements of providing the sequence of GenBank Accession Number X62841 with an associated sequence identifier, the claims still do not comply with the sequence rules because claim 4 still recites the GenBank Accession Number X62841 and not the proper sequence identifier.

SEAN MCGARRY PRIMARY EXAMINER

2